Skip to main
IDYA

IDYA Stock Forecast & Price Target

IDYA Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 42%
Buy 50%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

IDEAYA Biosciences is quickly advancing their lead drug candidate, IDE849, through clinical trials, with data reported from the Hengrui-sponsored China study and initial data set to be reported from their own Phase 1 study later this year. The company has promising efficacy data for IDE849, showing a potential best-in-class profile in treating relapsed/refractory ES-SCLC and epNEC, with response rates and progression-free survival estimates exceeding those of competing ADCs. They have also received positive feedback from the FDA regarding their Phase 3 study design, and their recent offering has bolstered their financial position for future growth.

Bears say

IDEAYA Biosciences is facing significant competition in the market for its oncology-focused precision medicine products, and its clinical-stage product candidates have only reached the Phase 1 stage, with potentially more risk and uncertainty in their outcomes. With projected sales estimates for peak revenue being adjusted and a low upside potential compared to downside risk, the current market price is overvalued. Additionally, with a limited portfolio of only a few product candidates, IDEAYA may face challenges in diversifying its revenue streams and achieving sustainable growth.

IDYA has been analyzed by 12 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 50% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ideaya Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ideaya Biosciences Inc (IDYA) Forecast

Analysts have given IDYA a Buy based on their latest research and market trends.

According to 12 analysts, IDYA has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $54.58, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $54.58, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ideaya Biosciences Inc (IDYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.